ProKidney Corp.
McKenzie Christopher Pitts has a diverse work experience. They began their career as a Human Resources Assistant at Care Ventures Inc in 2012 before moving on to Flagship Rehabilitation as an Assistant Manager. In 2016, McKenzie joined Anchor Rehabilitation as a Director of Rehab and later transitioned to Flagship Rehabilitation as an Outpatient Compliance Officer. In 2017, McKenzie pursued a different path as a Professional Cheerleader for the Baltimore Ravens. In 2020, they became a Regulatory Compliance Manager at MetLife. Currently, McKenzie holds the role of Clinical Quality Assurance Consultant at ProKidney Corp, and will soon transition into the position of Senior Manager, Clinical Quality Assurance Lead.
McKenzie Christopher Pitts has a Bachelor of Applied Science (B.A.Sc.) in Allied Health Sciences/Administration and Management from Towson University, which was obtained from 2016 to 2018. Prior to that, McKenzie also earned an Associate's Degree in Applied Science in Occupational Therapy Assistant from Allegany College of Maryland, attending from 2012 to 2014. Additionally, McKenzie pursued Pre-Occupational Therapy Studies at West Virginia University from 2010 to 2012. In terms of certifications, McKenzie obtained a First Aid, AED & CPR certification from the American Red Cross in 2012.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.